ANI PHARMACEUTICALS ($ANIP) is expected to release its quarterly earnings data on Friday, May 9th before market open, per Finnhub. Analysts are expecting revenue of $184,295,772 and earnings of $1.41 per share.
You can see Quiver Quantitative's $ANIP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ANI PHARMACEUTICALS Insider Trading Activity
ANI PHARMACEUTICALS insiders have traded $ANIP stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $ANIP stock by insiders over the last 6 months:
- NIKHIL LALWANI (PRESIDENT & CEO) has made 0 purchases and 2 sales selling 33,481 shares for an estimated $1,941,442.
- STEPHEN P. CAREY (SVP & CFO) sold 7,500 shares for an estimated $418,425
- CHRISTOPHER MUTZ (HEAD OF RARE DISEASE) sold 6,500 shares for an estimated $375,050
- ORI GUTWERG (SVP, GENERICS) has made 0 purchases and 2 sales selling 5,384 shares for an estimated $323,049.
- KRISTA DAVIS (SVP, CHIEF HR OFFICER) has made 0 purchases and 4 sales selling 4,866 shares for an estimated $302,350.
- MEREDITH COOK (SR. VP, GENERAL COUNSEL & SEC.) has made 0 purchases and 6 sales selling 2,100 shares for an estimated $127,700.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ANI PHARMACEUTICALS Hedge Fund Activity
We have seen 93 institutional investors add shares of ANI PHARMACEUTICALS stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 473,097 shares (+89.3%) to their portfolio in Q4 2024, for an estimated $26,152,802
- UBS GROUP AG added 308,322 shares (+107.6%) to their portfolio in Q4 2024, for an estimated $17,044,040
- JPMORGAN CHASE & CO removed 286,785 shares (-51.7%) from their portfolio in Q4 2024, for an estimated $15,853,474
- ABRDN PLC added 237,965 shares (+inf%) to their portfolio in Q4 2024, for an estimated $13,154,705
- ASSENAGON ASSET MANAGEMENT S.A. removed 196,999 shares (-63.2%) from their portfolio in Q1 2025, for an estimated $13,189,083
- MORGAN STANLEY removed 174,751 shares (-43.5%) from their portfolio in Q4 2024, for an estimated $9,660,235
- SIO CAPITAL MANAGEMENT, LLC added 160,051 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,847,619
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ANI PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ANIP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 03/05/2025
To track analyst ratings and price targets for ANI PHARMACEUTICALS, check out Quiver Quantitative's $ANIP forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
